Capitalmind
Capitalmind
Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial

1 ArticlesAlmirall

1 / 1

Sun Pharma – Almirall Enter Into Agreement for Tildrakizumab Inhibitor for Treatment Against Psoriasis

Sun Pharmaceutical Industries and Almirall – the spanish giant announced a licensing agreement on the development and commercialization of tildrakizumab ...

Jul 28, 2016

Sun-Pharma-Share-Price-28-July-2016.png

Join Capitalmind Premium

Starts at ₹1,999/mo

Get access to our equity, fixed income, macro and personal finance research, model equity and fixed-income portfolios, exclusive apps, tutorials, and member community.